help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Kluijver, J.
Right arrow Articles by Sterk, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Kluijver, J.
Right arrow Articles by Sterk, P. J.
American Journal of Respiratory and Critical Care Medicine Vol 166. pp. 294-300, (2002)
© 2002 American Thoracic Society

Original Article

Asymptomatic Worsening of Airway Inflammation during Low-Dose Allergen Exposure in Asthma

Protection by Inhaled Steroids

Josephine de Kluijver, Christine E. Evertse, Jasmijn A. Schrumpf, Hilly van der Veen, Aeilko H. Zwinderman, Pieter S. Hiemstra, Klaus F. Rabe and Peter J. Sterk

Departments of Pulmonology and Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands

Correspondence and requests for reprints should be addressed to Josephine de Kluijver, Lung Function Laboratory, C2-P-62 Leiden University Medical Center, P.O. Box 9600, NL-2300 RC, Leiden, The Netherlands. E-mail: j.de_kluijver{at}lumc.nl

Asthma is a chronic inflammatory disease that persists even during adequate therapy and asymptomatic episodes. We questioned whether "silent" chronic allergen exposure can induce and maintain airway inflammation and whether this still occurs during regular treatment with inhaled steroids. Twenty-six patients with house dust mite allergy and mild asthma (dual responders) participated in a parallel, double-blind study. All patients inhaled a low-dose of allergen on 10 subsequent working days (Days 1–5, 8–12). They were treated with 400 µg budesonide once daily (n = 13) or placebo (n = 13) from Days -3 to 19. At baseline (Day -6) and on Days 5, 12, and 19 we measured the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20), and percent eosinophils, interleukin (IL)-5/interferon-{gamma} messenger RNA ratio (in sputum cells by real-time reverse transcription-polymerase chain reaction [RT-PCR]), and eosinophilic cationic protein (ECP) in induced sputum. Symptoms, peak expiratory flow (PEF), FEV1, and exhaled nitric oxide (NO) were recorded repeatedly during the study. In the placebo group, repeated low-dose allergen exposure resulted in a significant increase in sputum eosinophils (p = 0.043), ECP (p = 0.011), IL-5/IFN-{gamma} messenger RNA ratio (p = 0.04), and in exhaled NO (p = 0.001), without worsening of symptoms, PEF, or baseline FEV1 (p > 0.07). In the budesonide group, the changes in PC20, sputum ECP, and exhaled NO were significantly different as compared with the placebo group (p < 0.03). We conclude that repeated low-dose allergen exposure in asthma can lead to airway inflammation without worsening of symptoms, which can be prevented by inhaled steroid treatment. This suggests that antiinflammatory therapy is beneficial during allergen exposure, even during asymptomatic episodes.

Key Words: asthma • airway hyperresponsiveness • induced sputum • eosinophils • inhaled steroids




This article has been cited by other articles:


Home page
 ChestHome page
M. M. Kelly, J. Chakir, D. Vethanayagam, L.-P. Boulet, M. Laviolette, J. Gauldie, and P. M. O'Byrne
Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge.
Chest, September 1, 2006; 130(3): 741 - 753.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. M. Slats, J. K. Sont, R. H.C.J. van Klink, E. H.D. Bel, and P. J. Sterk
Improvement in bronchodilation following deep inspiration after a course of high-dose oral prednisone in asthma.
Chest, July 1, 2006; 130(1): 58 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Ihre, P. Gyllfors, L. E. Gustafsson, M. Kumlin, and B. Dahlen
Early rise in exhaled nitric oxide and mast cell activation in repeated low-dose allergen challenge
Eur. Respir. J., June 1, 2006; 27(6): 1152 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
G. L. Colice
Categorizing Asthma Severity: An Overview of National Guidelines
Clin. Med. Res., August 1, 2004; 2(3): 155 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. de Kluijver, C. E. Evertse, J. K. Sont, J. A. Schrumpf, C. J. G. van Zeijl-van der Ham, C. R. Dick, K. F. Rabe, P. S. Hiemstra, and P. J. Sterk
Are Rhinovirus-induced Airway Responses in Asthma Aggravated by Chronic Allergen Exposure?
Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1174 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. Kips, B. J. O'Connor, S. J. Langley, A. Woodcock, H. A. M. Kerstjens, D. S. Postma, M. Danzig, F. Cuss, and R. A. Pauwels
Effect of SCH55700, a Humanized Anti-Human Interleukin-5 Antibody, in Severe Persistent Asthma: A Pilot Study
Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1655 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society